Comparative studies have confirmed that endoscopic examination is superior to barium radiology in the diagnosis of acute upper gastrointestinal bleeding. In general more diagnoses are made, and the overall proportions which are correct are also greater. If management is aided then logically: a) mortality rates should fall and/or, b) operation rates should change and/or length of hospital stay should be reduced. Available data do not suggest that any such gains have occurred. Thus in a recently completed study of 1037 patients who were randomly allocated to investigation by endoscopy (E) or barium meal radiology (R) by conventional double-contrast techniques, mortality rates (E 8,4 % and R 7,6 %) operation rates (E 18,1% and' R 18,2 %) as well as average length of hospital stay were virtually identical [1 ] .
If overall advantages cannot be discerned then specific benefits in individual subgroups should be sought. Two groups of lesions which tend to be missed by radiological investigation are acute mucosal lesions and oesophageal varices. Acute mucosal lesions seem to vary considerably in the frequency with which they are found endoscopically, and so far no clear explanation is available for (say) the high prevalence in Glasgow, Scotland and in the U.S.A. in New York and Detroit, but much lower figures in Scotland in Aberdeen and in the U.S.A. in Portland and Houston [2] . Though some superficial lesions, particularly if generalised, bleed severely, the great majority are self-limiting, and do not present a further hazard to health. Whether they are diagnosed positively or their presence inferred from negative radiology may therefore matter little.
Though oesophageal varices may be detected radiologically, diagnostic precision is less than with endoscopy, and endoscopy offers the important advantage that bleeding which is occurring from varices or from other associated lesions can be distinguished, management of each differing radically. In areas where hepatic cirrhosis is common endoscopy may therefore confer advantages in the management of haematemesis and melaena, though the extent of any gain is unclear.
The mortality rate in bleeding chronic ulcer is high in elderly people, about a quarter of patients aged over 70 years dying. Examination of this mortality suggests that deaths can be divided into three broad groups : a) those where coincident severe disease such as heart failure or cancer of the lung inhibited active management; b) deaths following operation, usually due to complications such as pneumonia and cardiovascular disease ; and c) some, usually, a few, deaths ascribed to continued bleeding.
Conventional wisdom suggests that early operative intervention is beneficial, there are no controlled trials, and an equally sound case can be made for suggesting that an aggressive early operative policy replaces deaths from bleeding by post-operative deaths. Comparisons of results in our hospitals, one of which had a more active interventionist policy than the other whilst admitting patients with bleeding of equivalent severity from the same area, showed no evidence of benefit in terms of a reduced mortality rate [3] . In the same hospitals over a five year period the operation rate for bleeding peptic ulcer, gastric or duodenal, has fallen from about a third to a fifth with no change in overall mortality.
If an operative policy is to be avoided then two problems remain; can effective means of stemming continued ulcer haemorrhage be introduced, and is the risk of further bleeding so high that continued prophylaxis is necessary ?
A variety of methods of stemming bleeding have been devised. So far there is no convincing evidence that drug treatment helps. Cimetidine seems to have no specific advantages; and though antifibrinolysis has proved promising in some hands, confirmation of its value is needed.
Endoscopic methods have included the use of cyanoacrylate tissue glues, electrocoagulation and laser application. Theoretical promise has not been matched by practical demonstration of value. This may not reflect actual tack of value so much as difficulty in showing a change in any individual measure indicating success or failure.
The choice of measures logically includes changes in death rates, operation rates and transfusion requirements. If mortality rates are chosen as the prime indicator then the triallist has to recognise the difficulties which prevail in trying to show a fall in a relatively low mortality rate. Taken overall the mortality rate associated with haematemesis and melaena is about ten per cent. A halving of this mortality, an impressive achievement, would require the admission of a very large number of cases to detect such an improvement. Table 1 A shows the sample sizes required in treated and control groups to detect a fall in mortality rate form 10 to 5 % and from 15 to 5%. A modest level of significance requires large numbers, and these are clearly excessive if the power of the test, that is its chances of detecting a difference if truly present, are to be adequate. Thus to have four chances in five of detecting a halving of mortality from 10 to 5 %, over a thousand cases are needed, whilst reduction to a half and half chance still needs over 500 cases. In this context the triallist is in a worse position than the cardiologist who in assessing the value of drugs in myocardial infarction starts from a mortality rate of about twenty per cent, and still has considerable difficulty in obtaining reliable results. Concentration on an individual subgroup, such as gastric ulcers, with a higher mortality gives greater scope for benefit, but has the disadvantage that only a minor (if sizeable) proportion of cases are eligible for the trial, and so the time for completion is lengthened. Recourse to operation is another possible index, but here there is the possible confounding factor that the indications for operation are based more upon belief of what is useful than upon knowledge. The proportions needing operations probably lie between a fifth and a third in d,uodenal~ and gastric ulcer, and if firm criteria could be defined, reduction in operation rates could be useful. However, the likely size of patient series still remains high. Thus Table 1 B shows that to detect reliably nineteen times out of twen, ty), a fall in operation rate from 40 to 20 % at a significance level of one in fifty would require 360 cases.
A remaining criterion is transfusion requiremeat. This is affected in part by the severity of blood loss before treatment, and in part by the clinician's judgement of need, which may differ from actual need. It is probably the weakest criterion of all, yet related most directly to what we wish to measure.
Given these problems, it is unsurprising that few successful clinical trials in haematemesis and melaena have been conducted, and the majority of data consist of small numbers giving inconclusive results. Such findings would not be acceptable in, say, the assessment of secondary prevention of myocardial infraction, should they be so in examining the value of treatments for haematemesis and melaena ? 
